Hoang-Xuan T, Frot P, Denis J, Pouliquen Y
J Fr Ophtalmol. 1984;7(2):125-31.
The relative efficacy of aciclovir (ACV) and trifluorothymidine (TFT) was evaluated in a randomized, open clinical trial of 37 patients with herpetic kerato-uveitis. Twenty-one patients were treated with ACV and 16 with TFT. Topical steroids were withheld as long as the degree of inflammation permitted. Although both drugs were effective in healing the herpetic corneal ulcers, TFT had a significantly shorter healing time than ACV. However, ACV was more effective in treating the iridocyclitis than TFT. In 5 cases the keratouveitis responded to ACV alone, while only one case was successfully managed with TFT alone. Both drugs seemed to prevent steroid-induced epithelial complications and no significant side-effects were observed with either drug. The treatment of herpetic keratouveitis with single agents such as ACV and TFT is dependent upon rapidly instituting therapy and minimizing the use of topical steroids. The apparently good intraocular penetration of ACV and TFT may decrease the need for adjunctive steroid therapy and thereby minimize the risks of facilitated viral replication and steroid-dependence.
在一项针对37例疱疹性角膜葡萄膜炎患者的随机开放临床试验中，评估了阿昔洛韦（ACV）和三氟胸腺嘧啶核苷（TFT）的相对疗效。21例患者接受ACV治疗，16例接受TFT治疗。只要炎症程度允许，就不使用局部类固醇。虽然两种药物在愈合疱疹性角膜溃疡方面均有效，但TFT的愈合时间明显短于ACV。然而，ACV在治疗虹膜睫状体炎方面比TFT更有效。5例角膜葡萄膜炎仅对ACV有反应，而仅1例单独使用TFT成功治愈。两种药物似乎都能预防类固醇诱导的上皮并发症，且两种药物均未观察到明显的副作用。使用ACV和TFT等单一药物治疗疱疹性角膜葡萄膜炎取决于迅速开始治疗并尽量减少局部类固醇的使用。ACV和TFT明显良好的眼内渗透性可能会减少辅助类固醇治疗的需求，从而将促进病毒复制和类固醇依赖的风险降至最低。
